BamSEC and AlphaSense Join Forces
Learn More

Altimmune Inc.

NASDAQ: ALT    
Share price (12/27/24): $7.67    
Market cap (12/27/24): $546 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 11 pages ​ Employment Agreement
12/34/56
EX-10.30
from 10-K 11 pages Employment Agreement
12/34/56
EX-10.7
from 10-K 2 pages ​ Altimmune, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 8-K 10 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.1
from 10-Q 3 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.2
from 10-Q 9 pages Statement of Work
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 6 to Second Restated License Agreement
12/34/56
EX-10.22
from 10-K 6 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.15
from 10-K 3 pages Amendment No. 5 to Second Restated License Agreement
12/34/56
EX-10.1
from 8-K 6 pages February 25, 2021 Altimmune, Inc. 910 Clopper Road, Suite 201s Gaithersburg, Maryland 20878 Re: 3(a)(9) Exchange Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Altimmune, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 4 to Second Restated License Agreement
12/34/56
EX-10.3
from 10-Q 5 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed. Amendment No. 3 to Second Restated License Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Amendment No. 2 to Second Restated License Agreement
12/34/56
EX-10.4
from 10-Q 10 pages Employment Agreement
12/34/56
EX-10.3
from 10-Q ~50 pages Certain Information Identified by Bracketed Asterisks ([* * *]) Has Been Omitted From This Exhibit Because It Is Both Not Material and Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.2
from 10-Q 21 pages Amended and Restated License Agreement by and Between Mederis Diabetes, LLC and Spitfire Pharma, Inc. ` Amended and Restated License Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Release of Claims
12/34/56
EX-10.1
from 10-Q 11 pages Altimmune, Inc. Transition Services Agreement
12/34/56